Sanguine is Discussing a Project with the U.S. Army Medical Corps.

PASADENA, Calif. -- Sanguine Corp. (OTC BB: SGNC), a bio-pharmaceutical company focused on the development of an oxygen-carrying synthetic substitute for human red blood cells, announced that it is conferring with the U.S. Army Medical Corps to develop a "golden hour" medical kit using PHER-O2. Such a kit could allow self-transfusion on the battlefield, thus helping to prevent bleeding to death, which is a major cause of fatality in combat, and which continues to be the case in Iraq, despite the improvements in front line medical care.

Thomas Drees, Ph.D., chairman and CEO of Sanguine Corp., stated, "In treating battlefield injuries, time is often critical to survivability. If a 'golden hour' kit can be developed, either self-transfusion or field transfusion by a medic could allow a wounded soldier a better opportunity at survival. This could be possible since PHER-O2 does not require refrigeration nor type and crossmatching, which is necessary with packed red cells."

Sanguine Corp. is a development-stage company focused on the research and development of PHER-O2, a synthetic red blood cell product with potential applications in a variety of specialties, including: transfusions, CAT scans, cardioplegia and the treatment of heart attacks, strokes, head and neck tumors and hemorrhagic shock. The company is also developing non-medical applications for its perfluorocarbon (PFC) product.

Forward-looking statements in this release are made pursuant to the "safe harbor" provisions of the Private Securities Litigation Reform Act of 1995. Investors are cautioned that such forward-looking statements involve risks and uncertainties, including without limitation, continued acceptance of the company's products, increased levels of competition for the company, new products and technological changes, the company's dependence on third-party suppliers, and other risks detailed from time to time in the company's periodic reports filed with the Securities and Exchange Commission. A list of the potential risk factors that may affect the company's prospects may be found in the company's most recent 10K filing. These risk factors should be read in conjunction with this press release.